InferVision, a provider of medical artificial intelligence (AI) with a focus on deep learning and AI-based clinical applications, has completed its Series D2 financing led by Goldman Sachs Asset Management. The company has raised 140 million dollars from Series D1 and Series D2 financings. The proceeds will be used to expand distribution channels and expand business development.
CK, Founder, and Chairman of InferVision, said, “We are excited to have a proven, global investor like Goldman Sachs lead this latest round of financing. We view the collaboration with them as recognition of our capabilities in developing advanced AI solutions in healthcare. Our company aims to utilize rapidly evolving technology to bring about a significant improvement in medical services.”
AI-powered detection and triage systems offered by InferVision aim to increase clinical efficiency and improve the health of patients while reducing the costs associated with health care. InferVision develops AI applications, data mining, and research platforms using AI and deep learning technologies.
InferVision’s AI solution speeds up pneumonia diagnosis and epidemic monitoring. The InferRead Pneumonia COVID-19 screening system was launched by InferVision during the current pandemic worldwide in hospitals and medical institutions. With the product’s success, the European Union (EU) has decided to collectively purchase the screening system in over nine different countries.
Xinyi Feng, a managing director in Goldman Sachs Asset Management, said, “While healthcare has undergone significant evolution, the application of AI technologies to accelerate medical diagnosis stands out as one of the most compelling opportunities to benefit and innovate for a large addressable market in the future. We look forward to helping InferVision achieve this dynamic vision that could have a profound impact on healthcare.”
